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This study aimed to improve the water solubility of amiodarone hydrochloride (AMH) via inclusion 
complexes with β-cyclodextrin, methyl-β-cyclodextrin and 2-hydroxypropyl-β-cyclodextrin. Inclusion 
complexes were developed by physical mixture, coevaporation, spray-drying and freeze-drying. Solid state 
analysis was performed using X-ray powder diffraction, differential scanning calorimetry and scanning 
electronic microscopy. Thermodynamic studies demonstrate that the inclusion complexes of drug into 
different cyclodextrins were an exothermic process that occurred spontaneously. Water solubility and 
drug dissolution rates were significantly increased after the formation of inclusion complexes with the 
cyclodextrins evaluated in relation to the physical mixture and pure drug. The present study provides 
useful information for the potential application of complexation with amiodarone HCl. This may be a 
good strategy for the development of solid pharmaceutical dosage forms. 
Uniterms: Amiodarone HCl/evaluation. Amiodarone HCl/solubility. Cyclodextrins/inclusion complexes. 
Cyclodextrins /thermodynamic studies. Dissolution rate.
INTRODUCTION
Amiodarone hydrochloride (AMH), chemically 
known as (2-butylbenzofuran-3-yl)[4-[2-(diethylamino)
ethoxy]-3,5-diiodophenyl]methanone hydrochloride, used 
for the treatment of both supraventricular and ventricular 
arrhythmias (Lafuente-Lafuente et al., 2009). AMH is 
a white or almost white, crystalline powder and is very 
slightly soluble in water (0.2 – 0.5 mg mL-1) (British 
Pharmacopoeia, 2012; Eghrary et al., 2012). According 
to the Biopharmaceutical Classification System (BCS), 
AMH is a class II. Class II drugs are those with low 
solubilities and high permeabilities (Amidon et al., 1995; 
Benet, 2005). 
For drugs with low gastrointestinal solubility and 
high permeability, dissolution in physiological fluids is 
the limiting step for oral bioavailability. These properties 
are a challenge for the pharmaceutical industry, since more 
than 70% of the new drugs have low solubility showing 
deficient biopharmaceutical properties (Ku, Dublin, 2012; 
Leuner, Dressman, 2000; Riekes et al., 2010; Svenson, 
2009; Vasconcelos, Sarmento, Costa, 2007). 
In order to improve drug solubility in physiological 
fluids, their effectiveness should be increased, and the 
doses administered and toxic effects reduced. Several 
strategies can be employed, such as development of solid 
dispersion, inclusion complexes containing cyclodextrin, 
chemical modification, particle micronization, pH 
adjustment, micellar solubilization and supercritical fluid 
(Adeli, 2014; Alves et al., 2014; Chaudhary et al., 2012; 
Frizon et al., 2013; Gursoy, Benita, 2004; Jagdale et al., 
2012; Li-hong et al., 2013; Lu et al., 2012; Maulvi et al., 
2011; Patel et al., 2008; Sathigari et al., 2009).
Cyclodextrins (CDs) are cyclic organic compounds 
composed of different D-glucopyranose units. CDs 
containing six, seven or eight natural glucose units 
obtained in high quantity called α-cyclodextrin (α-CD), 
β-cyclodextrin (β-CD) and γ-cyclodextrin (γ-CD), 
respectively. These structures showed different values 
of solubility in water and at the same time are capable of 
hosting hydrophobic molecules (Loftsson, Brewster, 1996; 
Rajewski, Stella, 1996; Uekama, 2004). 
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This work aimed to develop inclusion complexes 
using cyclodextrins for the purpose of improving water 
solubility and dissolution rate of AMH. The solid state 
physicochemical properties were assessed using powder 
X-ray diffraction, differential scanning calorimetry, 
Fourier-transform infrared spectroscopy and scanning 
electron microscopy. Furthermore, in vitro dissolution 
profiles using different dissolution media were performed 
to investigate the increased solubility of this drug. 
MATERIAL AND METHODS
Material
AMH (purity > 99%) was obtained from Brazilian 
Pharmacopeia, batch 1040. The raw material AMH batch: 
CAD20131006 (purity>99%) was purchased from Zhejiang 
Pharmaceutica® (Hong Kong, China). β-Cyclodextrin 
(β-CD), methyl-β-cyclodextrin, (Methyl-β-CD) and 
hydroxypropyl-β-cyclodextrin (HP-β-CD), with an average 
degree of molar substitution per anhydroglucose unit of 0.6, 
purchased from Sigma-Aldrich® (St. Louis, MO, USA). 
Ultra-pure deionized water was generated from a Millipore 
Milli-Q Gradient System (Billerica, MA, USA). Other 
reagents and solvents used were of analytical grade.
Preparation of physical mixture and inclusion 
complexes 
Physical mixture and inclusion complexes of AMH 
and CDs at a 1:1 molar ratio were performed by different 
techniques: 
Physical mixture (PM): The PM was prepared by 
mixing previously weighed powders in a ceramic mortar 
for 10 min.
Coevaporation (CE): The product was prepared by 
dissolving a known amount of AMH and CDs in suitable 
volumes of water:ethanol (1:1) solution. The mixture 
was stirred for 2 hours and then solvent was removed in a 
vacuum oven at 40 ºC for 72 hours. 
Freeze-drying (FD): The product was prepared by 
dissolving the CDs in water:ethanol (1:1) solution and 
adding a known amount of AMH. The mixture was agitated 
for 5 h at 40 ºC and organic solvent was evaporated by 
rotary evaporation at 40 ºC under reduced pressure (-700 
mm Hg) (Fisatom®, model 802). The solution was placed 
in a freezer at –80 ºC for 24 hours and lyophilized in a 
Jouan LP3 (model 60) freeze-dryer for 24 hours.
Spray-drying (SD): The product was prepared 
by dissolving the CDs in water:ethanol (1:1) solution 
and adding a known amount of AMH. The mixture was 
agitated for 24 h at 25 ºC. The mixture was spray-dried 
using a LabMaq Brazil ® (model MSDi 1.0 ) spray dryer 
under the following conditions: sample feed rate of 4 mL/
min, inlet temperature 135 ºC, outlet temperature 105 ºC 
and air flow rate of 45 L/min.
 
pH-Dependent solubility and Phase solubility 
studies
The pH-dependent solubil i ty studies were 
determined in pH 1.2, 4.5 and 6.8 buffer solution and 
distilled water at 37 ºC ± 0.5 ºC. An excess quantity of 
AMH was placed in an erlenmeyer flask containing 10 
mL of different solutions. The samples were covered to 
avoid solvent loss and then shaken at 140 rpm in an orbital 
shaking incubator (Novatecnica®, NT712) for 24 hours. 
After equilibrium, samples were centrifuged at 4000 rpm 
for 10 minutes, and then the concentration of AMH in 
supernatant liquid was determined by HPLC (Rubim et 
al., 2015). 
The phase solubility studies were performed 
according to the method reported by Higuchi and 
Connors (1965). Briefly, an excess amount of AMH was 
transferred to an erlenmeyer flask containing 10 mL 
cyclodextrins in aqueous solutions at concentrations 
ranging from 0 to 10.0 mM. The flasks were covered 
to avoid solvent loss and then shaken at 140 rpm in 
an orbital shaking incubator for 24 hours at different 
temperatures 25 ºC and 37 ºC ± 0.5 ºC. After equilibrium, 
samples were centrifuged at 4000 rpm for 10 minutes, 
and then the concentration of AMH in supernatant liquid 
was determined by HPLC. All the experiments were 
performed in triplicate. The apparent complexation 
constants (K1:1, M-1) of the complexes were determined 
in accordance with Eq. (1) from phase solubility slope, 




Thermodynamic parameters were obtained as a 
function of the temperature and complexation constant. 
The changes in Gibb’s free energy (ΔG), enthalpy (ΔH) 
and entropy (ΔS) were determined using (Eq (2), (3) and 
(4)), respectively, where R is the gas constant (8.314 J 
mol-1 K-1) and T is temperature in Kelvin.
  (2)
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Characterization of the inclusion complex 
X-ray powder diffraction analysis (XRD) 
The diffraction patterns of samples were obtained 
with a X-ray diffractometer (Rigaku®, Miniflex 300), using 
Cu as an anode material, operated at a voltage of 10 mA, 
30 kV, monochromatic radiation (λ = 1.54051 Å). The 
samples were analyzed from 5º to 50º in the range of 2θ, 
in increments of 0.09 º/s. 
Differential Scanning Calorimetry (DSC) 
The DSC studies were obtained in a DSC-60 cell 
(Shimadzu®) with a sensibility of 0.1 oC, using aluminum 
crucibles with about 2 mg of sample. The temperature of 
analysis was 30 to 300 ºC, with a heating rate of 10 ºC min-1 
in a nitrogen atmosphere with a flow rate of 100 mL min-1. 
Scanning Electron Microscopy (SEM) 
With the help of the scanning electron microscope 
(Philips, Model XL 30) at an intensity of 10 kV, the 
samples were mounted onto a metallic base using double-
sided adhesive tape vacuum-coated with gold. 
Dissolution studies
The dissolution studies were performed in 500 mL 
dissolution medium (i.e. water, acid buffer pH 1.2, acetate 
buffer pH 4.5 and phosphate buffer 6.8) at 37 ºC ± 0.5 ºC 
using USP Apparatus 2 at 50 rpm. Briefly, AMH (50  mg), 
the physical mixture (PM) and inclusion complexes 
containing equivalent amount of AMH were separately 
added into vessel at a rotation speed of 50 rpm. At a pre-
specified interval time, samples (10 mL) were collected 
and replaced with an equal volume of fresh medium to 
maintain a constant total volume. The percentage of drug 
dissolved was determined using the HPLC method.
RESULTS AND DISCUSSION 
pH-Dependent solubility and Phase solubility 
studies
The solubility of AMH as a function of pH was 
determined in various aqueous media (water, acid buffer 
pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 
6.8). The solubility values found were: in water, 21.86 ± 
1.6011 µg mL-1; in acid buffer pH 1.2, 8.33 ± 0.1162 µg 
mL-1; in acetate buffer pH 4.5, 26.93 ± 0.2944 µg mL-1; 
in phosphate buffer pH 6.8, 1.18 ± 0.0877 µg mL-1. In 
solutions with low pH the AMH has appreciable solubility 
due to its basic nature and ionization (6.56 ± 0.06). On the 
other hand it is obvious that AMH shows low solubility 
in a higher pH solution in which it remains in a unionized 
form (Lamprecht, Bouligand, Benoit, 2002; Paduraru et 
al., 2013). 
The solubility behaviors found are according to the 
low solubility obtained with acid buffer pH 1.2. This can 
be explained as due to the formation of insoluble complex 
between drug and anions dissolved in buffer solution 
(Avdeef, 2007; Boury et al., 2001; Ravin, Shami, Rattie, 
1975).
Phase solubility studies were used for the evaluation 
of AMH behavior in an aqueous solution of β-CD, 
methyl-β-CD and HP-β-CD at 25 and 37 ºC. The results 
are shown in Figure 1. AMH solubility linearly increased 
with increasing concentrations of cyclodextrins over the 
concentration range evaluated. 
FIGURE 1 - Phase solubility diagrams of AMH in the presence of cyclodextrins in (A) 25 ºC and (B) 37 ºC ± 0.5 ºC (n = 3).
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The diagrams obtained were classified as AL 
type, according to Higuchi and Connors (1965). This 
classification is observed when the guest solubility 
increases linearly with the cyclodextrin concentration, 
over the concentration range evaluated, indicating a 
1:1 molecular complex formation between AMH and 
different cyclodextrins. The solubility of AMH in water 
increased significantly (more than 7, 14 and 9-fold at 
25 ºC) for β-CD, Methyl-β-CD and HP-β-CD at 10 
mM, respectively and (more than 4, 8 and 5-fold at 
37 ºC) for β-CD, Methyl-β-CD and HP-β-CD at 10 
mM, respectively. This increased solubility can be 
explained by the formation of an inclusion complex 
with cyclodextrins. The thermodynamics parameters 
(K1:1, ΔG, ΔH, ΔS) were calculated from the slopes of 
the linear phase-solubility plots, and are summarized in 
Table I.
The high (K1:1) values were observed for all 
cyclodextrins evaluated in this study, indicating the 
formation of a stable complex. The stability constants 
were highest for the complex formed with Methyl-β-CD, 
followed by HP-β-CD and β-CD. It has been suggested 
that the steric effect, which depends on the size of 
cyclodextrins, is one of the main factors of inclusion 
complex formation (Del Valle, 2004).
Furthermore the ΔG values were negative for all 
complexes, indicating that the inclusion of AMH in the 
different cyclodextrins is a spontaneous process and 
thermodynamically favorable. This increase in solubility 
is directly associated with values of ΔG tr<0 being 
proportional to the increased carrier concentration (Patel 
et al., 2008). The values of the enthalpy change (ΔH) were 
negative, indicating that the interaction between AMH 
and cyclodextrins is an exothermic process, nonetheless 
the magnitude of the change suggests that the interactions 
were of the low energy type. 
Characterization of the complexes
X-ray powder diffraction analysis
X-ray analysis is a tool utilized to characterize 
the crystalline state, to evaluate the different crystalline 
forms and also to confirm the formation of host-guest 
inclusion complexes. The solid state form of the particles 
as amorphous, crystalline or polymorphic is a parameter 
that determines the solubility and dissolution rate of drugs 
(Markovich et al., 1997). Figure 2 shows the diffractogram 
pattern of AMH and corresponding inclusion complexes 
with CDs prepared by different methods.
Figure 2 shows the intense peaks of crystalline 
state of the drug structure and the influence that each 
CD and preparation method can have on the crystalline 
state of the drug. The PM product using the three carriers 
showed a diffractogram pattern similar to that of the 
pure drug. The CE method using β-CD showed a similar 
diffractogram to that of PM, while those obtained by 
SD and FD methods showed the absence of any peaks 
indicating a transition from crystalline to an amorphous 
state. Similar results were observed with Methyl-β-
CD and HP-β-CD by spray-drying and freeze-drying 
methods. This solid state form transition was also 
observed by Bankar and Mahatma (2012), Paduraru et al. 
(2013) and Riekes et al. (2010), when the amorphization 
of the compounds after complexation with cyclodextrins 
was demonstrated.
Thermal analysis
DSC is a tool utilized in the pharmaceutical industry 
for the purpose of evaluating the physicochemical 
properties of drugs and excipients, evaluation of 
degradation kinetics and stability. Furthermore, these 
analyses are commonly used to characterize the solid 
state inclusion complexes (Vecchio et al., 2001; 
TABLE I - Thermodynamic parameters obtained from phase solubility studies with AMH and cyclodextrins at different temperatures 
(values are the mean ± SD of triplicate experiments) 
Systems TA SoB K1:1C ΔGD ΔSE ΔHF
AMH:β-CD
25 0.009 ± 0.001 446.23 ± 2.1985 -15.12 ± 0.8952 -58.46 ± 0.9211
32.55 ± 0.3911
37 0.015 ± 0.002 268.46 ± 1.6874 -14.42 ± 1.0283 -58.46 ± 0.0391
AMH:Methyl-β-CD
25 0.008 ± 0.004 1135.22 ± 2.2021 -17.44 ± 1.2418 -23.51 ± 0.7769
24.45 ± 1.5885
37 0.013 ± 0.004 775.19 ± 1.5733 -17.16 ± 0.8496 -23.50 ± 1.2059
AMH:HP-β-CD
25 0.011 ± 0.003 458.72 ± 2.9982 -15.19 ± 1.8541 -38.16 ± 1.3361
20.10 ± 1.0211
37 0.018 ± 0.011 335.19 ± 3.5874 -14.99 ± 0.1774 -16.48 ± 0.5587
A Temperatures evaluated in (ºC); B Solubility of AMH in the absence of cyclodextrins (mM); C Apparent complexation constant 
(M-1); D Change in Gibbs-free energy (KJ mol-1); E Change in entropy (J mol-1 K-1); F Change in enthalpy (KJ mol-1).
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Yoshida et al., 2011). The thermal behavior of the drug, 
cyclodextrins and inclusion complexes are presented in 
Figure 3.
The DSC curve shows that AMH has a sharp 
melting endothermic peak at about 163.47 ºC, indicating 
a typical behavior of the anhydrous crystalline state. 
This DSC curve was similar to those in other studies 
(Paduraru et al., 2013, Riekes et al., 2010). During the 
DSC analysis the thermogram of HP-β-CD showed a very 
broad endothermic peak between 60 ºC and 110 ºC. The 
formulations produced by different methods containing the 
three cyclodextrins showed a reduction of intensity and an 
alteration in position of the endothermic peak of the drug. 
When the spray-drying method was utilized, the complete 
disappearance of the endothermic peak corresponding 
to AMH was evident, indicating the formation of an 
amorphous inclusion complex that was confirmed by the 
results obtained after XRD analysis.
FIGURE 2 - X-ray diffractograms corresponding to: (A): 1 – AMH, 2 - β-CD, 3 – AMH/β-CD/PM, 4 – AMH/β-CD/CE, 5 – AMH/β-
CD/SD, 6 – AMH/β-CD/FD, (B): 1 – AMH, 2 - Methyl-β-CD, 3 – AMH/Methyl-β-CD/PM, 4 – AMH/Methyl-β-CD/CE, 5 – AMH/
Methyl-β-CD/SD, 6 – AMH/Methyl-β-CD/FD and (C): 1 - AMH, 2 - HP-β-CD, 3 – AMH/HP-β-CD/PM, 4 – AMH/HP-β-CD/CE, 
5 – AMH/HP-β-CD/SD, 6 - AMH/HP-β-CD/FD.
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Scanning electron microscopy
The images obtained for the formulations are 
presented in Figure 4. The micrographs are used to 
evaluate the morphological aspects of polymers, solid 
dispersions, drugs, cyclodextrins and inclusion complexes 
(Naidu et al., 2004). 
AMH showed the irregular size and characteristic 
morphology of drug crystals, which is in accordance 
with the X-ray analysis that showed the crystalline nature 
of AMH. It was also evident that β-CD is a crystalline 
solid while Methyl-β-CD and HP-β-CD are regular and 
spherical particles.
In the physical mixtures and coevaporation method 
the AMH crystals were clearly detectable on the surface 
of cyclodextrins indicating little complexation between 
compounds. All spray dried powders showed an interaction 
between drug and cyclodextrins, indicated by the complete 
disappearance of the crystalline morphology of AMH. 
This drastic change of morphology and particle shape was 
indicative of the formation of the new solid phase. Results 
obtained by others evaluations, DSC and X-ray powder 
corroborated the formation of an amorphous system.
Dissolution rate studies 
In drugs that present low gastrointestinal solubility 
and high permeability, in this case AMH, the oral 
drug release is a limiting step for bioavailability. The 
bioavailability depends on a series of factors, including 
the physicochemical properties of its formulation, and 
the physiological state of the patients (Fernandes, Vieira, 
Veiga, 2002).
To evaluate whether the inclusion complexes 
affected the dissolution rates of AMH, dissolution profiles 
were performed on pure drug, physical mixtures and 
inclusion complexes with cyclodextrins, with three pH 
values and water. Rapid dissolution rate as compared with 
the pure drug is the characteristic behavior of inclusion 
complexes (Baboota, Dhaliwal, Kohli, 2005). Dissolution 
profiles for the pure AMH, physical mixture of the drug 
and inclusion complexes obtained by different methods 
are presented in Figure 5. 
Pure AMH shows about 22.20% dissolution in water, 
7.83%, 18.31% and 4.82% dissolution in acid buffer pH 
1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8, 
respectively after 60 minutes of study. As expected, AMH 
is a drug that depends on the pH value due to the presence 
of a tert-amine ionizable in different fluids (Paduraru et 
al., 2013). 
The physical mixtures containing the three 
cyclodextrins show a similar dissolution rate of about 
30% at 60 minutes in water and acetate buffer pH 4.5. 
The increment in the dissolution rate of AMH with the 
physical mixture can be explained by improved drug 
wettability due to the presence of the cyclodextrins, which 
can reduce the interfacial tension between particle and 
dissolution medium. The coevaporation, spray-drying 
and freeze-drying methods of β-CD, Methyl-β-CD and 
HP-β-CD showed a significant increase in drug dissolution 
compared to physical mixture. This can be attributed to the 
better interaction between drug and CDs, as confirmed by 
physicochemical characterization. 
The spray-drying products with methyl-β-CD 
showed about 55%, 56%, 65% and 38% dissolution 
in water, acid buffer pH 1.2, acetate buffer pH 4.5 and 
phosphate buffer pH 6.8, respectively. The great influence 
of methyl-β-CD can be explained based on its good 
FIGURE 3 - DSC thermograms: 1: (A) AMH powder, (B) 
physical mixture, (C) spray-dried, (D) coevaporated, (E) β-CD 
and (F) freeze-dried; 2: (A) AMH powder, (B) spray-dried, (C) 
coevaporated, (D) physical mixture, (E) freeze-dried and (F) 
Methyl-β-CD; and 3: (A) AMH powder, (B) spray-dried, (C) 
coevaporated, (D) physical mixture, (E) freeze-dried and (F) 
HP-β-CD. 
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FIGURE 4 - Scanning Electronic Microscopy of AMH, beta-CD, methylbeta-CD, hydroxypropylbeta-CD, AMH/beta-CD/PM (1A), 
AMH/beta-CD/CE (1B), AMH/beta-CD/SD (1C), AMH/beta-CD/FD (1D), AMH/methylbeta-CD/PM (2A), AMH/methylbeta-
CD/CE (2B), AMH/methylbeta-CD/SD (2C), AMH/methylbeta-CD/FD (2D), AMH/hydroxypropylbeta-CD/PM (3A), AMH/
hydroxypropylbeta-CD/CE (3B), AMH/hydroxypropylbeta-CD/SD (3C) and AMH/hydroxypropylbeta-CD/FD (3D).
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FIGURE 5 - Dissolution curves of AMH powder and different formulations using: (A) water, (B) acid buffer pH 1.2, (C) acetate 
buffer pH 4.5 and (D) phosphate buffer pH 6.8 as dissolution medium at 37 ºC ± 0.5 ºC.
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solubility, higher amorphization, wettability and capacity 
of complexation in solid state (Fernandes, Vieira, Veiga, 
2002).
CONCLUSIONS
In the present work, the complex formed between 
AMH and CDs presented an enhanced solubility and 
dissolution rate for all complexes formed other than either 
physical mixture or pure drug. AMH solubility linearly 
increases with increasing concentrations of CDs of both 
temperatures indicating an AL-type diagram over the 
entire concentration range evaluated. The ΔGtr values were 
negative for all formulations indicating a spontaneous 
process which was thermodynamically favorable to 
drug solubility. The Kc result suggests good stability for 
both temperatures evaluated of the inclusion complex 
formed by AMH-Methyl-β-CD. The characterization 
of physicochemical results confirmed the formation of 
complexes with different cyclodextrins. The dissolution 
profiles of formulations demonstrated the great influence 
on drug solubility especially when prepared by the spray-
drying method with methyl-β-CD for all dissolution 
mediums evaluated. After studies using different CDs and 
complexation process, the results obtained demonstrated 
that the CDs are good excipients to increase molecule 
solubility. 
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